Enanta Pharmaceuticals (ENTA) to Release Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) will be releasing its earnings data after the market closes on Monday, November 20th. Analysts expect Enanta Pharmaceuticals to post earnings of ($2.11) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Enanta Pharmaceuticals Trading Up 5.1 %

Shares of ENTA opened at $9.13 on Friday. Enanta Pharmaceuticals has a 12 month low of $8.08 and a 12 month high of $62.06. The stock’s 50 day moving average is $10.14 and its two-hundred day moving average is $17.41. The firm has a market cap of $192.23 million, a P/E ratio of -1.45 and a beta of 0.48.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sei Investments Co. purchased a new stake in Enanta Pharmaceuticals in the third quarter valued at $535,000. AQR Capital Management LLC raised its position in Enanta Pharmaceuticals by 608.1% in the third quarter. AQR Capital Management LLC now owns 137,776 shares of the biotechnology company’s stock valued at $1,539,000 after purchasing an additional 118,320 shares during the period. Tower Research Capital LLC TRC raised its position in Enanta Pharmaceuticals by 207.2% in the third quarter. Tower Research Capital LLC TRC now owns 6,224 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 4,198 shares during the period. Qube Research & Technologies Ltd raised its position in Enanta Pharmaceuticals by 149.3% in the third quarter. Qube Research & Technologies Ltd now owns 113,672 shares of the biotechnology company’s stock valued at $1,270,000 after purchasing an additional 68,076 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in Enanta Pharmaceuticals in the third quarter valued at $115,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ENTA. Jefferies Financial Group lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the stock from $49.00 to $18.00 in a research note on Tuesday, August 8th. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 29th. JMP Securities lowered their price target on Enanta Pharmaceuticals from $65.00 to $42.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 8th. JPMorgan Chase & Co. lowered Enanta Pharmaceuticals from a “neutral” rating to an “underweight” rating and set a $14.00 price target on the stock. in a research note on Wednesday, August 9th. Finally, HC Wainwright lowered their price target on Enanta Pharmaceuticals from $48.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $35.00.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.